

PMDA-ATC Pharmaceuticals Review Webinar 2021

Date: Dec 6-8, 2021

1. Pre-live self-learning

| Session | Duration |
|--|-----------------|
| 1. Review Team | 2 min |
| 2. Application Dossier | 3 min |
| 3. Review Process | 3 min |
| 4. Achievements | 2.5 min |
| 5. Toxicology studies | 6 min |
| 6. Good Laboratory Practice | 2 min |
| 7. First in Human studies | 5.5 min |
| 8. Good Clinical Practice | 3 min |
| 9. GCP inspection procedure in Japan | 6.5 min |
| 10. Review of Generic drugs | 5.5 min |
| 11. Review of Biosimilars | 9.5 min |
| 12. Expedited regulatory pathways | 10 min |
| 13. Start of Clinical Trial to NDA/MAA | 20 min |
| 14. Review of New Drugs | 20 min |
| Total | 98.5 min |

2. Live sessions

| Day 1 Monday, Dec. 6 | Day 2 Tuesday, Dec. 7 | Day 3 Wednesday, Dec. 8 |
|---|---|---|
| 14:00 - 14:10 Opening Remarks | 14:00-16:45 Session 4 Case Study (Review of New Drugs) - Introduction (30min) - Group Discussion (70min) - Group Presentation and Commentary plus Q&A (65 min) | 14:00-14:50 Session 5 Review of Chemistry, Manufacturing and Control (CMC) - Lecture (20min) - Q&A (30min) |
| 14:10-14:40 Session 1 New drug approval review - Lecture(20min) - Q&A (10min) | | 14:50-15:50 Session 6 Case Study (Review of Generic Drugs) - Introduction (10min) - Group Discussion (30min) - Commentary and Q&A (20 min) |
| 14:40-15:10 Session 2 Consultation meetings - Lecture (20min) - Q&A (10min) | | 15:50 - 16:00 Closing Remarks |
| 15:10-15:40 Session 3 Regulatory Challenge against COVID-19 - Lecture (15min) - Q&A (15min) | | 16:00 - 16:10 Evaluation of Day 3 |
| 15:40-15:50 Evaluation of Day 1 | 16:45 - 16:55 Evaluation of Day 2 | |